Prediction of outcome after diagnosis of metachronous contralateral breast cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Alkner, Sara ^a,b   Bendahl, Pär Ola ^a   Fernö, Mårten ^a   Manjer, Jonas ^a,b   Rydén, Lisa ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adjuvant therapy; Detection; metachronous breast cancer contralateral breast cancer; Prognosis

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; METACHRONOUS CONTRALATERAL BREAST CANCER; PREDICTION; PROGNOSIS; SWEDEN; SYMPTOMATOLOGY; TREATMENT OUTCOME; AGE; AGED; BREAST TUMOR; CARCINOMA; DIAGNOSIS; METASTASIS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; SECOND CANCER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; SWEDEN;

EID: 79954602547     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-114     Document Type: Article

References (42)

1. Adami HO, Bergstrom R, Hansen J. Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study. Cancer 1985, 55(3):643-647. 10.1002/1097-0142(19850201)55:3<643::AID-CNCR2820550328>3.0.CO;2-L, 3965112.
2. Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar ML, Rotstein S, Perveck L, Ringborg U. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. Journal of the National Cancer Institute 1991, 83(18):1299-1306. 10.1093/jnci/83.18.1299, 1886157.
3. Alkner S, Bendahl PO, Ferno M, Nordenskjold B, Ryden L. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. Eur J Cancer 2009, 45(14):2496-2502. 10.1016/j.ejca.2009.05.022, 19535242.
4. Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, Dickman PW, Hall P. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 2007, 25(27):4210-4216. 10.1200/JCO.2006.10.5056, 17878475.
5. Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trichopoulos D, Adami HO, Hall P. Genetic implications of bilateral breast cancer: a population based cohort study. The lancet oncology 2005, 6(6):377-382. 10.1016/S1470-2045(05)70174-1, 15925815.
6. Brommesson S, Jonsson G, Strand C, Grabau D, Malmstrom P, Ringner M, Ferno M, Hedenfalk I. Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs. BMC clinical pathology 2008, 8:6. 10.1186/1472-6890-8-6, 2474633, 18616792.
7. Imyanitov EN, Hanson KP. Molecular pathogenesis of bilateral breast cancer. Cancer letters 2003, 191(1):1-7. 10.1016/S0304-3835(02)00523-2, 12609703.
8. Shibata A, Tsai YC, Press MF, Henderson BE, Jones PA, Ross RK. Clonal analysis of bilateral breast cancer. Clin Cancer Res 1996, 2(4):743-748.
9. Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S, Rudas M, Gnant M, Jakesz R. Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat 2001, 67(1):1-8. 10.1023/A:1010661514306, 11518461.
10. Verkooijen HM, Chatelain V, Fioretta G, Vlastos G, Rapiti E, Sappino AP, Bouchardy C, Chappuis PO. Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat 2007, 105(3):347-357. 10.1007/s10549-006-9455-x, 17186359.
11. Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer 2000, 88(12):2739-2750. 10.1002/1097-0142(20000615)88:12<2739::AID-CNCR12>3.0.CO;2-J, 10870056.
12. Takahashi H, Watanabe K, Takahashi M, Taguchi K, Sasaki F, Todo S. The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer. Breast cancer (Tokyo, Japan) 2005, 12(3):196-202.
13. Dawson LA, Chow E, Goss PE. Evolving perspectives in contralateral breast cancer. Eur J Cancer 1998, 34(13):2000-2009. 10.1016/S0959-8049(98)00208-1, 10070301.
14. Burns PE, Dabbs K, May C, Lees AW, Birkett LR, Jenkins HJ, Hanson J. Bilateral breast cancer in northern Alberta: risk factors and survival patterns. Canadian Medical Association journal 1984, 130(7):881-886. 1875971, 6322952.
15. Quan G, Pommier SJ, Pommier RF. Incidence and outcomes of contralateral breast cancers. American journal of surgery 2008, 195(5):645-650. discussion 650, 10.1016/j.amjsurg.2008.01.007, 18424281.
16. Kuo WH, Yen AM, Lee PH, Chen KM, Wang J, Chang KJ, Chen TH, Tsau HS. Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. British journal of cancer 2009, 100(4):563-570. 10.1038/sj.bjc.6604898, 2653740, 19190627.
17. Holmberg L, Adami HO, Ekbom A, Bergstrom R, Sandstrom A, Lindgren A. Prognosis in bilateral breast cancer. Effects of time interval between first and second primary tumours. British journal of cancer 1988, 58(2):191-194. 10.1038/bjc.1988.191, 2246768, 3166909.
18. Carmichael AR, Bendall S, Lockerbie L, Prescott R, Bates T. The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol 2002, 28(4):388-391. 10.1053/ejso.2002.1266, 12099647.
19. Lu W, Schaapveld M, Jansen L, Bagherzadegan E, Sahinovic MM, Baas PC, Hanssen LM, van der Mijle HC, Brandenburg JD, Wiggers T, De Bock GH. The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer. Eur J Cancer 2009, 45(17):3000-3007. 10.1016/j.ejca.2009.08.007, 19744851.
20. Rubino C, Arriagada R, Delaloge S, Le MG. Relation of risk of contralateral breast cancer to the interval since the first primary tumour. British journal of cancer 2010, 102(1):213-9. 10.1038/sj.bjc.6605434, 2813760, 19920826.
21. Imyanitov EN, Suspitsin EN, Grigoriev MY, Togo AV, Kuligina E, Belogubova EV, Pozharisski KM, Turkevich EA, Rodriquez C, Cornelisse CJ, Hanson KP, Theillet C. Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas. International journal of cancer 2002, 100(5):557-564.
22. Hemminki K, Granstrom C. Morphological types of breast cancer in family members and multiple primary tumours: is morphology genetically determined?. Breast Cancer Res 2002, 4(4):R7. 10.1186/bcr444, 116721, 12100745.
23. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365(9453):60-62. 10.1016/S0140-6736(04)17666-6, 15639680.
24. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. Journal of the National Cancer Institute 1996, 88(21):1529-1542. 10.1093/jnci/88.21.1529, 8901851.
25. Systemic treatment of early breast cancer by hormonal cytotoxic or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992, 339(8785):71-85.
26. Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. Journal of the National Cancer Institute 2004, 96(7):516-523. 10.1093/jnci/djh097, 15069113.
27. Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol 2005, 23(21):4687-4694. 10.1200/JCO.2005.04.076, 15837971.
28. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361(9354):296-300. 10.1016/S0140-6736(03)12342-2, 12559863.
29. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA 1994, 271(20):1587-1592. 10.1001/jama.271.20.1587, 8182811.
30. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 1994, 271(20):1593-1597. 10.1001/jama.271.20.1593, 7848404.
31. Lu WL, Jansen L, Post WJ, Bonnema J, Van de Velde JC, De Bock GH. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat 2009, 114(3):403-412. 10.1007/s10549-008-0023-4, 18421576.
32. Houssami N, Ciatto S, Martinelli F, Bonardi R, Duffy SW. Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol 2009, 20(9):1505-1510. 10.1093/annonc/mdp037, 19297316.
33. Jacobs HJ, van Dijck JA, de Kleijn EM, Kiemeney LA, Verbeek AL. Routine follow-up examinations in breast cancer patients have minimal impact on life expectancy: a simulation study. Ann Oncol 2001, 12(8):1107-1113. 10.1023/A:1011624829512, 11583192.
34. Grunfeld E, Noorani H, McGahan L, Paszat L, Coyle D, van Walraven C, Joyce J, Sawka C. Surveillance mammography after treatment of primary breast cancer: a systematic review. Breast (Edinburgh, Scotland) 2002, 11(3):228-235.
35. de Bock GH, Bonnema J, van der Hage J, Kievit J, van de Velde CJ. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. J Clin Oncol 2004, 22(19):4010-4018. 10.1200/JCO.2004.06.080, 15459225.
36. Lawrence G, Wallis M, Allgood P, Nagtegaal ID, Warwick J, Cafferty FH, Houssami N, Kearins O, Tappenden N, O'Sullivan E, Duffy SW. Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias. Breast Cancer Res Treat 2009, 116(1):179-185. 10.1007/s10549-008-0100-8, 18622697.
37. Duffy SW, Nagtegaal ID, Wallis M, Cafferty FH, Houssami N, Warwick J, Allgood PC, Kearins O, Tappenden N, O'Sullivan E, Lawrence G. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. American journal of epidemiology 2008, 168(1):98-104. 10.1093/aje/kwn120, 18504245.
38. Paci E, Coviello E, Miccinesi G, Puliti D, Cortesi L, De Lisi V, Ferretti S, Mangone L, Perlangeli V, Ponti A, Ravaioli A, de' Bianchi PS, Segnan N, Stracci F, Tumino R, Zarcone M, Zorzi M, Zappa M, . IMPACT Working Group Evaluation of service mammography screening impact in Italy. The contribution of hazard analysis. Eur J Cancer 2008, 44(6):858-865. 10.1016/j.ejca.2008.02.026, 18359222, IMPACT Working Group.
39. Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, Greenberg DC, Pharoah P, Caldas C, Wishart GC. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. British journal of cancer 2009, 101(8):1338-1344. 10.1038/sj.bjc.6605317, 2768460, 19773756.
40. Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. Jama 2004, 292(9):1064-1073. 10.1001/jama.292.9.1064, 15339900.
41. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. Journal of the National Cancer Institute 2005, 97(16):1195-1203. 10.1093/jnci/dji239, 16106024.
42. Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH, Purushotham AD, Duffy SW. Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone?. British journal of cancer 2008, 98(11):1741-1744. 10.1038/sj.bjc.6604368, 2410118, 18506175.